LENZ NASDAQ
LENZ Therapeutics, Inc.
1W: -8.7%
1M: -38.3%
3M: -36.1%
YTD: -77.6%
1Y: -92.7%
$3.58
-0.21 (-5.54%)
Weekly Expected Move ±8.8%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-11-16
Earliest Filing
2024-07-15
Latest Filing
partner: 3
supplier: 2
investor: 1
target: 1
acquirer: 1
customer: 1
Counterparties (Filed by LENZ)
9 relationshipsCompanies named in LENZ's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ridgeback Capital Investment, L.P. | — | investor | Purchased 1,578,947 shares of common stock in a private placement for approximately $30.0 million. | 2024-07-15 | View |
| Lenz Therapeutics, Inc. | LENZ | target | Target company in the merger agreement with Graphite Bio, Inc. | 2023-11-15 | View |
| Generate Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Graphite Bio, Inc. formed to merge with Lenz Therapeutics, Inc. | 2023-11-15 | View |
| Soleil Labs, LLC | — | customer | Tenant in a sublease agreement for office space | 2023-10-30 | View |
| Bayside Area Development, LLC | — | supplier | Landlord in the master lease and sublease agreement | 2023-10-30 | View |
| Bayside Area Development, LLC | — | partner | Landlord in lease agreement for office and laboratory space | 2021-12-20 | View |
| CBRE, Inc. | CBRE | partner | Broker listed in lease agreement | 2021-12-20 | View |
| T3 Advisors | — | partner | Broker listed in lease agreement | 2021-12-20 | View |
| Annexon, Inc. | ANNX | supplier | Sublandlord entering into a sublease agreement with Graphite Bio, Inc. | 2021-11-16 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Officer/Director Change | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-03-24 | Earnings Release; Exhibits | View | |
| 2026-01-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-12 | Other Events | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-08 | Other Events | View | |
| 2025-09-30 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-07-31 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-10 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-15 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events | View | |
| 2025-04-04 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-03-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-28 | Other Events; Financial Statements and Exhibits | View | |
| 2024-07-15 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2024-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR